The verdict
Our read at a glance.
Whether efpeglenatide's GLP-1-class cardiovascular and kidney benefits (shown in AMPLITUDE-O) are read accurately, alongside the fact that it remains investigational and unmarketed despite that evidence.
- The signal
- In the AMPLITUDE-O trial, efpeglenatide lowered major cardiovascular events and kidney outcomes versus placebo in people with type 2 diabetes and high cardiovascular or kidney risk, adding to the evidence that GLP-1 drugs protect the heart and kidneys, including in people already on other modern therapies. It also lowered blood sugar and weight, as GLP-1 drugs do.
- The unknown
- Whether it will ever be developed and approved, how it would compare with the marketed GLP-1 drugs, and what its stalled path says about translating outcome evidence into available treatments.
- Our read
- A GLP-1 drug whose evidence outran its availability: AMPLITUDE-O showed real heart and kidney benefits, but it was never marketed and remains investigational. Read it as a positive-trial drug that stalled commercially, useful evidence for the GLP-1 class, not an available treatment.
The mechanism
How it works.
Efpeglenatide is a long-acting copy of the gut-hormone signal GLP-1, built from exendin (the same starting point as exenatide) attached to a small antibody fragment that makes it last far longer in the body, so it can be given infrequently. Like other GLP-1 drugs, it curbs appetite, slows stomach emptying, and prompts the pancreas to release insulin when blood sugar is high, which lowers blood sugar and body weight. The GLP-1 class also protects the heart and kidneys, and efpeglenatide's large outcomes trial (AMPLITUDE-O) showed those benefits, even though the drug was not ultimately brought to market.
Safety & regulatory boundary
The consequential part.
Like other GLP-1 drugs, efpeglenatide causes nausea, vomiting, and diarrhea, especially early. It is investigational and not FDA-approved or marketed, so it is not an available treatment, and any 'efpeglenatide' sold outside a clinical trial would not be a legitimate approved product. Its evidence base is real but its status is unsettled.
What's next
What we're watching.
Whether development resumes and leads to approval anywhere, and how its outcome data are weighed against the approved GLP-1 and dual/triple agonists.
Context
Why this is discussed.
Efpeglenatide is a GLP-1 drug with an unusual story: it passed a big outcomes trial, showing fewer heart and kidney events, yet was not commercialized. It is a reminder that strong trial evidence and actual availability are two different things.
The evidence base
10 cited references.
Registered trials3
ClinicalTrials.gov · PHASE3 · COMPLETED · 2017-12-05
ClinicalTrials.gov · PHASE3 · TERMINATED · 2018-09-26
ClinicalTrials.gov · PHASE3 · TERMINATED · 2018-04-27
Indexed literature (PubMed)7
Gerstein HC et al. · N Engl J Med · 2021
Giugliano D et al. · Cardiovasc Diabetol · 2021
Gerstein HC et al. · Circulation · 2023
Qazi SU et al. · J Diabetes Metab Disord · 2024
Escobar J et al. · Cureus · 2023
Pratley RE et al. · Diabetes Obes Metab · 2019
Yoon KH et al. · Diabetes Obes Metab · 2020
Keep reading